Axsome Therapeutics (NASDAQ:AXSM) announced that the U.S. Food and Drug Administration has approved Auvelity for the treatment of agitation associated with dementia due to Alzheimer’s disease, expanding the product’s indications beyond major depressive disorder. The approval and the company’s commercialization plans were discussed on a conference call led by Chief Operating Officer Mark Jacobson, with […]